We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00532922
First Posted: September 21, 2007
Last Update Posted: June 9, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
September 20, 2007
September 21, 2007
June 9, 2009
April 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00532922 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Natural History, longitudinal, defined population
Asthma
Not Provided
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
310
November 2007
Not Provided

Inclusion Criteria:

  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
Sexes Eligible for Study: All
6 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT00532922
NIS-RCN-SYM-2006/1
Yes
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Zhou Xin Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Principal Investigator: Hong Jianguo Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
AstraZeneca
June 2009